• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Werewolf Therapeutics Inc. (Amendment)

    2/12/24 6:06:37 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOWL alert in real time by email
    SC 13G/A 1 tm245464d8_sc13ga.htm SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1 )*

     
    Werewolf Therapeutics, Inc.
    (Name of Issuer)
     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)
     

    95075A107

    (CUSIP Number)
     

    December 31, 2023

    (Date of event which requires filing of this statement)
             

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)
             

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

    CUSIP No. 95075A107

     

    13G/A Page 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Rubric Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,935,357 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,935,357 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,935,357 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.35%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

    CUSIP No. 95075A107

     

    13G/A Page 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    David Rosen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,935,357 shares of Common Stock

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,935,357 shares of Common Stock

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,935,357 shares of Common Stock

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.35%

    12

    TYPE OF REPORTING PERSON

    IN

                 

     

     

    CUSIP No. 95075A107

     

    13G/A Page 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Werewolf Therapeutics, Inc. (the "Issuer").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer's principal executive offices are located at 200 Talcott Ave, 2nd Floor, Watertown, Massachusetts, 02472.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the shares of Common Stock (as defined in Item 2(d) below) reported herein; and
         
      (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.

     

    Item 2(c). CITIZENSHIP:
       
      Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, $0.0001 par value per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      95075A107

     

     

    CUSIP No. 95075A107

     

    13G/A Page 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,

     

      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) x Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

        If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________

     

    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 36,192,248 shares of Common Stock outstanding as of November 10, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 filed with the Securities and Exchange Commission on November 14, 2023.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
     

    Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2. 

     

     

     

    CUSIP No. 95075A107

     

    13G/A Page 6 of 7 Pages

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 95075A107

     

    13G/A Page 7 of 7 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATED: February 12, 2024  
       
    RUBRIC CAPITAL MANAGEMENT LP  
       
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  
       
    /s/ David Rosen  
    DAVID ROSEN  

     

     

    Get the next $HOWL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOWL

    DatePrice TargetRatingAnalyst
    4/3/2024$12.00Mkt Outperform
    JMP Securities
    8/24/2023$9.00Outperform
    Wedbush
    6/6/2023$11.00 → $12.00Buy
    Jefferies
    11/19/2021$29.00 → $28.00Outperform
    SVB Leerink
    9/10/2021$26.00Buy
    BofA Securities
    More analyst ratings

    $HOWL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

    Fast Track Designation underscores the promise of Werewolf's INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company has received Fast Track Designation for the use of WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous melanoma after standard of care immunotherapy. WTX-124 is a conditionally activated interleukin 2 (IL-2) INDUKINE therapy. Fast Track Designation is intende

    10/8/25 8:00:00 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

    WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.Details for the poster presentations are as follows: Title: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanc

    10/3/25 9:00:00 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

    WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 2:00 PM EDT on Monday, September 8, 2025, at the H.C. Wainwright 27th Annual Global Investment Conference, taking place on September 8-10, 2025. A

    9/2/25 8:00:00 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOWL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Evnin Luke

    4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)

    6/13/25 4:10:08 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Morrison Briggs

    4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)

    6/13/25 4:10:15 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lazarus Alon

    4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)

    6/13/25 4:10:16 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOWL
    SEC Filings

    View All

    SEC Form 8-K filed by Werewolf Therapeutics Inc.

    8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer)

    10/6/25 4:33:20 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Werewolf Therapeutics Inc.

    SCHEDULE 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)

    8/14/25 4:48:35 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Werewolf Therapeutics Inc.

    10-Q - Werewolf Therapeutics, Inc. (0001785530) (Filer)

    8/14/25 7:11:15 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOWL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $487,188 worth of shares (536,426 units at $0.91) (SEC Form 4)

    4 - Werewolf Therapeutics, Inc. (0001785530) (Issuer)

    5/14/25 6:08:19 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOWL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JMP Securities initiated coverage on Werewolf Therapeutics with a new price target

    JMP Securities initiated coverage of Werewolf Therapeutics with a rating of Mkt Outperform and set a new price target of $12.00

    4/3/24 7:44:47 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Werewolf Therapeutics with a new price target

    Wedbush initiated coverage of Werewolf Therapeutics with a rating of Outperform and set a new price target of $9.00

    8/24/23 7:17:30 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Werewolf Therapeutics with a new price target

    Jefferies resumed coverage of Werewolf Therapeutics with a rating of Buy and set a new price target of $12.00 from $11.00 previously

    6/6/23 9:09:19 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOWL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Werewolf Therapeutics Inc.

    SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)

    11/14/24 4:04:06 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Werewolf Therapeutics Inc.

    SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)

    11/14/24 11:54:33 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Werewolf Therapeutics Inc.

    SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)

    11/13/24 4:30:24 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOWL
    Financials

    Live finance-specific insights

    View All

    Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

    Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the highest dose tested to date, cohort 4 (12 mg) - Safety data indicate WTX-124 is generally well-tolerated through cohort 4 with no dose limiting toxicities and no indication of vascular leak syndrome (VLS) or other typically severe IL-2-mediated toxicities - Preliminary data support the potential of WTX-124 to be a differentiated next-generation IL-2 compound by showing immune cell activation in the

    11/3/23 7:00:00 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

    Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation.Additional posters representing an expansive body of data demonstrating the potential of Werewolf's PREDATOR™ platform and INDUKINE™ product candidates will also be presented.Company to host conference call and webcast to review WTX-124 initial clinical results November 3, 2023, at 8:30 am ET WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the d

    10/31/23 9:00:00 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOWL
    Leadership Updates

    Live Leadership Updates

    View All

    Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

    WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. "Steve brings deep experience in strategic transactions to Werewolf at this critical tim

    4/17/25 8:00:00 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

    WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors. "I am thrilled to join Werewolf's board of directors as the company advances its novel INDUKINE molecules through clinical development," said Dr. Singhal. "Werewolf is demonstrating the power of the PREDATORTM protein engineering p

    2/24/25 7:30:00 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

    WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors. "Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy. I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules," sai

    1/4/24 4:05:00 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care